242 related articles for article (PubMed ID: 23089492)
41. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
42. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
43. Primary breast diffuse large B-cell lymphoma shows an activated B-cell-like phenotype.
Li D; Deng J; He H; Bu Y; Peng F; Tang X; Wang B; Lei Y; Zhang H; Xie P
Ann Diagn Pathol; 2012 Oct; 16(5):335-43. PubMed ID: 22569408
[TBL] [Abstract][Full Text] [Related]
44. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
[TBL] [Abstract][Full Text] [Related]
45. BAFF-R is expressed on B-cell lymphomas depending on their origin, and is related to proliferation index of nodal diffuse large B-cell lymphomas.
Takahata H; Ohara N; Ichimura K; Tanaka T; Sato Y; Morito T; Takata K; Kojima M; Kobata T; Yoshino T
J Clin Exp Hematop; 2010; 50(2):121-7. PubMed ID: 21123970
[TBL] [Abstract][Full Text] [Related]
46. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.
Lemma SA; Kuusisto M; Haapasaari KM; Sormunen R; Lehtinen T; Klaavuniemi T; Eray M; Jantunen E; Soini Y; Vasala K; Böhm J; Salokorpi N; Koivunen P; Karihtala P; Vuoristo J; Turpeenniemi-Hujanen T; Kuittinen O
Carcinogenesis; 2017 Aug; 38(8):812-820. PubMed ID: 28854563
[TBL] [Abstract][Full Text] [Related]
47. Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma.
Lim DH; Kim WS; Kim SJ; Yoo HY; Ko YH
Anticancer Res; 2015 Jun; 35(6):3333-40. PubMed ID: 26026093
[TBL] [Abstract][Full Text] [Related]
48. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
Deckert M; Montesinos-Rongen M; Brunn A; Siebert R
Acta Neuropathol; 2014 Feb; 127(2):175-88. PubMed ID: 24240734
[TBL] [Abstract][Full Text] [Related]
49. Clinical pathology of primary central nervous system lymphoma in HIV-positive patients-a 41 Chinese patients retrospective study.
Chen J; Sun L; Dai Y; Zhang L; Yang K; Han X; Ding X; Gao H; Zhou X; Wang P
Ann Diagn Pathol; 2023 Apr; 63():152108. PubMed ID: 36638601
[TBL] [Abstract][Full Text] [Related]
50. Discrepancy Between Low Levels of mTOR Activity and High Levels of P-S6 in Primary Central Nervous System Lymphoma May Be Explained by PAS Domain-Containing Serine/Threonine-Protein Kinase-Mediated Phosphorylation.
Marosvári D; Nagy N; Kriston C; Deák B; Hajdu M; Bödör C; Csala I; Bagó AG; Szállási Z; Sebestyén A; Reiniger L
J Neuropathol Exp Neurol; 2018 Apr; 77(4):268-273. PubMed ID: 29361117
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
Guo S; Bai Q; Rohr J; Wang Y; Liu Y; Zeng K; Yu K; Zhang X; Wang Z
APMIS; 2016 Dec; 124(12):1054-1062. PubMed ID: 27807891
[TBL] [Abstract][Full Text] [Related]
52. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathological correlates of primary central nervous system lymphoma: experience from a tertiary care center in South India.
Patel B; Chacko G; Nair S; Anandan J; Chacko AG; Rajshekhar V; Turel M
Neurol India; 2015; 63(1):77-82. PubMed ID: 25751474
[TBL] [Abstract][Full Text] [Related]
54. Metallothionein-I + II and receptor megalin are altered in relation to oxidative stress in cerebral lymphomas.
Pedersen MØ; Hansen PB; Nielsen SL; Penkowa M
Leuk Lymphoma; 2010 Feb; 51(2):314-28. PubMed ID: 20038220
[TBL] [Abstract][Full Text] [Related]
55. Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.
Yushi Q; Li Z; Von Roemeling CA; Doeppler H; Marlow LA; Kim BY; Radisky DC; Storz P; Copland JA; Tun HW
Oncotarget; 2016 May; 7(22):32156-71. PubMed ID: 27050077
[TBL] [Abstract][Full Text] [Related]
56. Expression of Tim-1 in primary CNS lymphoma.
Kishimoto W; Nishikori M; Arima H; Miyoshi H; Sasaki Y; Kitawaki T; Shirakawa K; Kato T; Imaizumi Y; Ishikawa T; Ohno H; Haga H; Ohshima K; Takaori-Kondo A
Cancer Med; 2016 Nov; 5(11):3235-3245. PubMed ID: 27709813
[TBL] [Abstract][Full Text] [Related]
57. Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.
Radotra BD; Parkhi M; Chatterjee D; Yadav BS; Ballari NR; Prakash G; Gupta SK
Surg Neurol Int; 2020; 11():424. PubMed ID: 33365186
[TBL] [Abstract][Full Text] [Related]
58. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.
Dunleavy K; Erdmann T; Lenz G
Cancer Treat Rev; 2018 Apr; 65():41-46. PubMed ID: 29549872
[TBL] [Abstract][Full Text] [Related]
59. CD47 and osteopontin expression in diffuse large B-cell lymphoma with nodal and intravascular involvement.
Starr JS; Jiang L; Li Z; Qiu Y; Menke DM; Tun HW
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):597-601. PubMed ID: 23810243
[No Abstract] [Full Text] [Related]
60. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
